A pair of airline incidents gave us a powerful reminder of 2 key safety rules: wear your seatbelt and leave your bag behind in an emergency
25 people were injured when a Delta flight hit turbulence, while American passengers evacuated with their bags.
Keeping your seatbelt on and leaving your bag behind in an emergency are simple, effective safety measures.
Passenger behavior can be key to preventing injuries, as two recent airline incidents have shown.
To be specific, always wear a seatbelt in case of sudden turbulence, and leave your bags behind in an emergency evacuation.
On Wednesday, 25 people were injured after a Delta Air Lines plane encountered "significant" turbulence while flying over Wyoming, the airline said.
Flight 56 diverted to Minnesota and landed safely, but over two dozen people were taken to nearby hospitals.
Turbulence can appear suddenly and isn't always detected by onboard radar systems, so there may not be time for the pilots to put on the seatbelt sign.
"It's essentially like taking a box with something in it and starting to shake the box up and down," Guy Gratton, an associate professor of aviation and the environment at Cranfield University, previously told Business Insider.
"If you're the person who's inside the box, then you get thrown around inside the box, and that's where injuries happen."
"Passengers are told to keep their seatbelts done up because if you're tied to the box, you're much less likely to get injured," he added.
Plus, turbulence is getting more common as a result of the climate crisis
Warmer temperatures allow the atmosphere to hold more moisture, increasing the likelihood and intensity of thunderstorms.
Clear-air turbulence, which occurs near jet streams, is also becoming stronger and more frequent due to changes in the atmosphere.
In 2023, researchers at the University of Reading in the UK found that severe air turbulence had increased 55% over a typical point in the North Atlantic Ocean between 1979 and 2020.
Leave your bags behind in an evacuation
Last Saturday, an American Airlines flight was evacuated at Denver International Airport when a landing gear caught fire before takeoff.
The airline said that all 173 passengers and six crew members on board were safely evacuated from the aircraft, while one person was taken to a hospital with minor injuries.
However, a video of the incident showed passengers carrying their luggage as they went down the emergency slides.
The Federal Aviation Administration warns on its website that "retrieving personal items may impede the safe evacuation of passengers."
Aviation expert Geoffrey Thomas previously told BI how this can cause bottlenecks on board, slowing down the evacuation.
"You've got to get all the passengers out in 90 seconds," he said. "Now, we're seeing evacuations taking six and seven minutes because passengers insist on taking their bags."
When a Japan Airlines Airbus A350 caught fire after colliding with another plane last January, all 379 people on board survived after evacuating in time.
Under safety rules, planemakers have to show that an aircraft can be evacuated in only 90 seconds with only half the exits available.
"Bear in mind that such tests do not take place in a high-stress environment," Graham Braithwaite, an expert on flight safety at Cranfield University, told BI at the time.
The airline's in-flight safety video was also praised for its clear evacuation instructions, and reminding passengers to leave their bags behind.
Not all fires end the same way.
In 2019, an Aeroflot plane caught fire after an emergency landing in Moscow, and 41 of the 78 people on board died.
Experts criticized passengers who evacuated with their carry-on luggage, suggesting it may have contributed to the death count.
While there were no fatalities in the American Airlines and Delta Air Lines incidents over the past week, both are stark reminders of how things can go wrong if safety rules aren't followed.
Read the original article on Business Insider
Solve the daily Crossword

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Exact Sciences (EXAS) To Report Earnings Tomorrow: Here Is What To Expect
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be reporting earnings this Wednesday after market close. Here's what to expect. Exact Sciences beat analysts' revenue expectations by 2.7% last quarter, reporting revenues of $706.8 million, up 10.9% year on year. It was a satisfactory quarter for the company, with full-year revenue guidance slightly topping analysts' expectations but a significant miss of analysts' EPS estimates. Is Exact Sciences a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Exact Sciences's revenue to grow 10.6% year on year to $773.1 million, slowing from the 12.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.05 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Exact Sciences has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 1.7% on average. Looking at Exact Sciences's peers in the biotechnology segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Regeneron delivered year-on-year revenue growth of 3.6%, beating analysts' expectations by 11.3%, and Incyte reported revenues up 16.5%, topping estimates by 5.5%. Regeneron traded up 4.8% following the results while Incyte was also up 10.5%. Read our full analysis of Regeneron's results here and Incyte's results here. Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the biotechnology stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.3% on average over the last month. Exact Sciences is down 9.1% during the same time and is heading into earnings with an average analyst price target of $68.55 (compared to the current share price of $47.70). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Long Covid Patients Can Sign up for Remote Clinical Trial Notification, Announces CareEvolution
At-home participation in a study by Scripps Research and Schmidt Initiative for Long Covid powered by CareEvolution's MyDataHelps® platform ANN ARBOR, Mich., August 05, 2025--(BUSINESS WIRE)--Long Covid patients around the U.S. looking to participate in a clinical trial from home can sign up to be notified when an upcoming study conducted by scientists at Scripps Research and supported by the Schmidt Initiative for Long Covid (SILC) opens. Patients can sign up on the Long Covid Treatment Trial (LoCITT) website. The upcoming study, powered by the MyDataHelps platform from CareEvolution, is a fully remote clinical trial investigating the efficacy of a repurposed drug for treating Long COVID. It will enroll 1,000 Long Covid patients from across the U.S. The app-based study enables participants to enroll and participate in all trial activities without having to visit a trial clinic. "Decentralized trials broaden reach, speed timelines and yield richer real-world evidence," said Vik Kheterpal, MD, a principal at CareEvolution. "LoCITT will help advance how efficiently we can run trials as we seek treatments for complex, heterogeneous conditions like Long Covid." Long Covid, which has affected the lives of 400 million people worldwide and costs the global economy an estimated $1 trillion per year, can often cause symptoms that make mobility and travel challenging for patients who want to participate in trials. The forthcoming Scripps Research-led trial will rely on the LoCITT platform to enroll patients, distribute drug candidates and placebos, as well as collect and evaluate trial data. "For people with severe Long Covid, travel can be dangerous," said Julia Moore Vogel, senior program director at the Scripps Research Translational Institute. "LoCITT enables even patients with the most severe symptoms to join the search for answers." Moore Vogel is co-principal investigator of the study alongside Scripps Research executive vice president Eric Topol. Remote trials, which eliminate the need for patients to report to clinics, enable easier and broader participation. Conducting a Long Covid trial remotely will also allow more representative cohorts—potentially leading to more generalizable findings. "We need aggressive, rapid efforts to turn the tide on this very difficult condition for all the patients who struggle with it," said John Redd, CEO of SILC. "We're hopeful that a remote trial will help us find effective treatments more quickly." CareEvolution adapted its existing MyDataHelps decentralized clinical trial platform specifically for the LoCITT trial, with the potential for it to be used by other research efforts. The platform will allow for patients to be screened, enrolled and randomized more swiftly. Potential treatments and placebos will be mailed directly to the participant's home, along with wearable devices and other technologies to collect patient data. CareEvolution's user-friendly platform allows patients to check their eligibility, provide consent electronically and respond to baseline and ongoing surveys about their symptoms. Patients selected for the study will receive wrist devices to monitor their heart rates, activity and sleep, potentially enabling the development of digital biomarkers for Long Covid and related conditions like myalgic encephalomyelitis (ME), which can cause debilitating fatigue, and postural orthostatic tachycardia syndrome (POTS), which can cause dizziness, fatigue and a rapid heart rate upon standing up. The data from the devices will be uploaded to LoCITT. Prospective participants who are 18 years of age or older and who believe they have Long Covid can sign up at to be notified when the Scripps clinical trial opens. About CareEvolution We Connect Healthcare. MyDataHelps®, our digital clinical trials platform, accelerates healthcare innovation by empowering researchers to configure and launch studies in hours. We enable anyone, anywhere to be able to participate in research using participant centric design that integrates surveys, wearable and sensor data, EHR connectivity, and participant engagement tools to generate robust real-world longitudinal data. Trusted by over 2.5 million participants enrolled in longitudinal initiatives sponsored by health systems, academic institutions, life science companies, foundations, and public health agencies, CareEvolution advances precision health and helps close critical gaps in our collective understanding of complex conditions. For more information please visit About the Schmidt Initiative for Long Covid The Schmidt Initiative for Long Covid (SILC) advances clinical care for Long Covid patients globally. The nonprofit organization, founded in 2023 by philanthropists Eric and Wendy Schmidt, works to raise the level of Long Covid care and understanding around the world, connecting specialists and primary care providers to support patients and share knowledge virtually, in real time. For more information, visit About Scripps Research Scripps Research is an independent, nonprofit biomedical institute ranked one of the most influential in the world for its impact on innovation by Nature Index. We are advancing human health through profound discoveries that address pressing medical concerns around the globe. Our drug discovery and development division, Calibr-Skaggs, works hand-in-hand with scientists across disciplines to bring new medicines to patients as quickly and efficiently as possible, while teams at Scripps Research Translational Institute harness genomics, digital medicine and cutting-edge informatics to understand individual health and render more effective healthcare. Scripps Research also trains the next generation of leading scientists at our Skaggs Graduate School, consistently named among the top 10 US programs for chemistry and biological sciences. Learn more at View source version on Contacts CareEvolutionpr@ Swati Pandey, SILCspandey@ Anna Andersen, Scripps Researchaanders@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


New York Times
3 hours ago
- New York Times
A Nuclear Reactor on the Moon? Come Again?
The acting administrator of NASA has issued a directive to fast-track efforts to put a nuclear reactor on the moon. 'To properly advance this critical technology to be able to support a future lunar economy, high power energy generation on Mars, and to strengthen our national security in space, it is imperative the agency move quickly,' Sean Duffy, the secretary of transportation whom President Trump appointed last month as temporary leader of the space agency, wrote in the directive, which was sent out on Thursday. Politico was first to report on the directive. In it, Mr. Duffy cites plans by China and Russia to put a reactor on the moon by the mid-2030s as part of a partnership to build a base there. If they were first, China and Russia 'could potentially declare a keep-out zone' that would inhibit what the United States could do there, Mr. Duffy said. The directive calls for the appointment of a NASA official to oversee the effort within 30 days and for a request seeking proposals from commercial companies to be issued within 60 days. The reactor will be required to generate at least 100 kilowatts of electrical power — enough for about 80 households in the United States — and to be ready to launch in late 2029. One lunar day lasts four weeks on Earth — two weeks of continual sunshine followed by two weeks of cold darkness. That harsh cycle makes it difficult for a spacecraft or a moon base to survive with just solar panels and batteries. Current exploration efforts, both by NASA and by the Chinese-Russian partnership, are focusing on the south polar region, where the sun is never high over the horizon and the bottoms of some craters lie in permanent shadows. Over the years, NASA has financed nuclear reactor research, including the awarding of three $5 million contracts in 2022 to companies developing initial designs. Those designs were smaller, producing 40 kilowatts and weighing under six metric tons. Want all of The Times? Subscribe.